Is AVITA Medical, Inc. (RCEL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 31.6% / 30% | 12.5% / 30% | 6.3% / 30% | 1.45% / 5% | ✗ NOT HALAL |
| DJIM | 31.6% / 33% | 12.5% / 33% | 6.3% / 33% | 1.45% / 5% | ✓ HALAL |
| MSCI | 81.7% / 33% | 32.2% / 33% | 16.1% / 33% | 1.45% / 5% | ✗ NOT HALAL |
| S&P | 31.6% / 33% | 12.5% / 33% | 6.3% / 33% | 1.45% / 5% | ✓ HALAL |
| FTSE | 81.7% / 33% | 32.2% / 33% | 16.1% / 50% | 1.45% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 82.1% | |
| Operating Margin | -59.1% | |
| Net Margin | -67.8% | |
| Return on Assets (ROA) | -39.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$31M |
| Free Cash Flow | -$33M |
| Total Debt | $46M |
| Current Ratio | 0.6 |
| Total Assets | $56M |
Price & Trading
| Last Close | $3.86 |
| 50-Day MA | $4.36 |
| 200-Day MA | $4.54 |
| Avg Volume | 229K |
| Beta | 1.8 |
|
52-Week Range
$3.22
| |
About AVITA Medical, Inc. (RCEL)
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is AVITA Medical, Inc. (RCEL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), AVITA Medical, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is AVITA Medical, Inc.'s debt ratio?
AVITA Medical, Inc.'s debt ratio is 31.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 81.7%.
What are AVITA Medical, Inc.'s key financial metrics?
AVITA Medical, Inc. has a market capitalization of $117M, and revenue of $72M. The company maintains a gross margin of 82.1% and a net margin of -67.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.